N.ByktunaS
Design and optimization of myricetin encapsulated nanostructured lipid carriers: in-vivo assessment against cognitive impairment in amyloid beta (142) intoxicated rats
Semaglutide is approved for both weight management and type 2 diabetes treatment, and it addresses both conditions through the same metabolic mechanism
The presence of obesity-related complications such as obstructive sleep apnea, metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD), or cardiovascular disease may justify longer treatment duration given the health benefits of sustained weight loss
*Correspondence: Yufei Liu, [email protected] Xu, [email protected] Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
Now offering treatment services in Naples, Fort Myers, Bonita Springs, Cape Coral (All SWFL), Miami, Tampa, Fort Lauderdale and Orlando, Florida including all throughout the United States
